Home › Bristol-Myers: FDA blocks hepatitis C drug for...
 

Keywords :   


Bristol-Myers: FDA blocks hepatitis C drug for...

2014-11-26 20:55:53| Biotech - Topix.net

U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir. The company said Wednesday that data it submitted to the Food and Drug Administration to win approval of daclatasvir focused on that drug's use with asunaprevir.

Tags: for drug blocks fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
20.09Construction giant collapses putting 2,400 jobs at risk
20.09KANSAI HELIOS Further Expands as System Supplier in Italy
More »